Q-omics provides the consensus-scored RTRAFP2 profile across patient tissues and cancer cell-line models. RTRAFP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RTRAFP2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RTRAFP2 RNA expression shows 6,634 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight STAD, COAD, and UCEC as cancer lineages where RTRAFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTRAFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTRAFP2 survival associations across molecular data types. RTRAFP2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTRAFP2 RNA expression–survival associations across cancer types. High RTRAFP2 expression shows unfavorable associations in STAD, LGG, LIHC and READ, but favorable associations in BLCA and UCEC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RTRAFP2 RNA expression.
This table summarizes RTRAFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RTRAFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTRAFP2 shows lower tumor expression in ESCA, LUAD and LUSC and higher tumor expression in COAD, KIRC and KIRP. The COAD box plot shows higher RTRAFP2 RNA expression in tumor versus normal tissue (log2 FC = +0.411, t-test p < 0.001).
This table shows molecular features associated with RTRAFP2 in patient tissues and cancer cell lines. In patient samples, RTRAFP2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
